@article{33316b0b22fb43729cd644d359be9cb9,
title = "Preliminary report: Treatment of type 3 hyperlipoproteinemia with mevinolin",
abstract = "Type 3 hyperlipoproteinemia (HLP) results from the accumulation in plasma of remnants of very low density lipoproteins (VLDL) due to a defect in apolipoprotein E. Current data suggest that VLDL remnants can be removed by the same receptors that remove low density lipoproteins (LDL). Mevinolin has been shown to enhance clearance of LDL by LDL receptors. In this study, mevinolin markedly lowered both VLDL remnants and LDL in a patient with type 3 HLP, presumably by increasing the activity of LDL receptors.",
author = "East, {Cara A.} and Grundy, {Scott M} and Bilheimer, {David W.}",
note = "Funding Information: From the Department of Internal Medicine and Center for Human Nutrition, University of Texas Health Science Center, Dallas. Supported by grant HL 29252 (NIH/HDS/DHHS). NIH grant MOI-RR00633 (General Clinical Research Center), VSPHS training grant AM 07307, the Southwestern Medical Foundation, and the Moss Heart Foundation, Dallas. Address reprint requests to Dr David W. Bilheimer, Department of Internal Medicine, University of Texas Health Science Center, 5323 Harry Hines, Dallas, TX 75235. o 1986 by Grune & Stratton, Inc. 0026-0495/86/3502~01$03.00/0",
year = "1986",
month = feb,
doi = "10.1016/0026-0495(86)90106-X",
language = "English (US)",
volume = "35",
pages = "97--98",
journal = "Metabolism",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",
}